In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemoteq's Fancy New Coat

Executive Summary

Hemoteq's hemocompatible coating for medical devices could help address one of the last remaining concerns about drug-eluting stents: the risk of subacute and late thrombosis. But for a small company to compete in drug-eluting stents isn't easy.

You may also be interested in...



TCT Highlights: Late Stent Thrombosis Controversy Continues

Late stent thrombosis (LST) concerns associated with drug-eluting stents (DES) dominated sessions at the 2006 Transcatheter Cardiovascular Therapeutics (TCT) annual conference, with additional long-term data presented on this topic. The general feeling expressed was one of relief that the expanded dataset presented at TCT showed the LST problem was not as bad as some had feared when the issue was discussed at the World Congress of Cardiology (WCC).

Boston Scientific Takes Conor to Court over DES

Boston Scientific has filed suite in the Netherlands to keep Conor Medsystems from selling its paclitaxel-coated stent in Europe. This is the latest effort by interventional cardiology companies to use litigation to protect market share.

Safety First For Perrigo In CBD Market; ‘Long-Term’ Play Starts With Clinical Trials

Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel